Giacomo Malipiero

Giacomo Malipiero

Auto-generated profile, based on publicly available information

Giacomo Malipiero

Personalized Medicine Asthma and Allergy, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089 Milan, Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2014 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
NCNicolã² Compagno
Nicolã² Compagno
GMGiacomo Malipiero
Giacomo Malipiero
FCFrancesco Cinetto
Francesco Cinetto
CACarlo Agostini
Carlo Agostini
Immunoglobulin (Ig) replacement therapy dramatically changed the clinical course of primary hypogammaglobulinemias, significantly reducing the incidence of infectious events. Over the last 2 decades its use has been extended to secondary antibody deficiencies, particularly those related to hematological disorders as lymphoproliferative diseases (LPDs) and multiple myeloma. In these malignancies, hypogammaglobulinemia can be an intrinsic aspect of the disease or follow chemo-immunotherapy regimens, including anti-CD20 treatment. Other than in LPDs the broadening use of immunotherapy (e.g. rituximab) and immune suppressive therapy (steroids, sulfasalazine, mycophenolate mophetil) has extended the occurrence of iatrogenic hypogammaglobulinemia. In particular, in both autoimmune diseases and solid organ transplantation Ig replacement therapy has been shown to reduce the rate of infectious events. Here, we review the existing literature about Ig replacement therapy in secondary hypogammaglobulinemia, with special regard for subcutaneous administration route, a safe, effective and well-tolerated treatment approach, currently well established in primary immunodeficiencies and secondary hypogammaglobulinemias.

25 May 2017 in Current Cardiology Reports
Verified
Journal Article
Closed access
PDF file
Alida CaforioAlida Caforio
Alida Caforio
GMG. Malipiero
G. Malipiero
RMR. Marcolongo
R. Marcolongo
SIS. Iliceto
S. Iliceto

1 September 2015 in Clinical and Molecular Allergy
Verified
Journal Article
Open access
PDF file
FCFrancesco Cinetto
Francesco Cinetto
NCNicolò Compagno
Nicolò Compagno
RSRiccardo SCARPA
Riccardo SCARPA
GMGiacomo Malipiero
Giacomo Malipiero
CACarlo Agostini
Carlo Agostini
Sarcoidosis is a granulomatous disease whose outcome varies from spontaneous remission to chronic refractory disease. Provided that steroids represent the gold standard as a first line treatment, many immune suppressants drugs are currently used in the disease management. However, refractory disease is still a great challenge. Rituximab is an anti-CD20 chimeric monoclonal antibody, currently used for the treatment of B cell malignancies and systemic autoimmune diseases. There are few case reports describing the successful use of Rituximab in refractory sarcoidosis with lung, eye, lymph nodes and skin involvement. In this paper we described three different case reports in which Rituximab has been used to treat refractory sarcoidosis and we reviewed the existing literature.

1 March 2012 in Journal Of Hypertension
Verified
Journal Article
Closed access
P1Paolo 11
Paolo 11
EBElisabetta Benetti
Elisabetta Benetti
CFClaudio Fania
Claudio Fania
GMGiacomo Malipiero
Giacomo Malipiero
FSFrancesca Saladini
Francesca Saladini
Objectives: Although the upper arm has the shape of a truncated cone, cylindrical cuffs and bladders are currently used for blood pressure (BP) measurement. The aim of this study was to ascertain whether cylindrical and tronco-conical cuffs provide different readings according to arm size and shape. Design: We studied 220 individuals with arm circumference ranging from 22 to 42.5 cm. Four different cylindrical and four different tronco-conical bladders of appropriate size were used. Sequential same-arm measurements were performed in triplicate by two observers using the two cuffs in a random order. In 100 individuals, the actual pressure transmitted to the arm surface by the two cuffs at the central point was also measured. Results: Upper arm shape was tronco-conical in all of the individuals. In a multiple regression, conicity was related to arm circumference (P < 0.001) and length (P = 0.001). Arm conicity and size were independently related to the between-cuff SBP (P = 0.001 and 0.002, respectively) and DBP (P = 0.001 and <0.001, respectively) discrepancies. In the group with arm circumference of 37.5–42.5 cm, the cylindrical cuff overestimated BP measured with the tronco-conical cuff by 2.0 ± 0.4/1.8 ± 0.3 mmHg (P = 0.001 and <0.001). In this group, 15% of individuals found hypertensive with the cylindrical cuff were normotensive when assessed with the conical cuff. Differences as great as 9.7/7.8 mmHg were found in individuals with large arms and slant angle equal to or less than 83°. Conclusion: In obese people, the upper arm may have a pronounced tronco-conical shape and cylindrical cuffs may overestimate BP. Tronco-conical cuffs should be used for BP measurement in individuals with large arms.

1 July 2020 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
GMGiacomo Malipiero
Giacomo Malipiero
Giovanni PaolettiGiovanni Paoletti
Giovanni Paoletti
FPFrancesca Puggioni
Francesca Puggioni
FRFrancesca Racca
Francesca Racca
SFSebastian Ferri
Sebastian Ferri
Enrico HefflerEnrico Heffler
Enrico Heffler

18 June 2020 in Clinical and Translational Allergy
Verified
Journal Article
Open access
PDF file
GMGiacomo Malipiero
Giacomo Malipiero
Enrico HefflerEnrico Heffler
Enrico Heffler
Corrado PelaiaCorrado Pelaia
Corrado Pelaia
FPFrancesca Puggioni
Francesca Puggioni
FRFrancesca Racca
Francesca Racca
Giovanni PaolettiGiovanni Paoletti
Giovanni Paoletti
Almost the entire World is experiencing the Coronavirus-Disease-2019 (COVID-19) pandemic, responsible, at the end of May 2020, of more than five million people infected worldwide and about 350,000 deaths. In this context, a deep reorganization of allergy clinics, in order to ensure proper diagnosis and care despite of social distancing measures expose, is needed. The reorganization of allergy clinics should include programmed checks for severe and poorly controlled patients, application of digital medicine service for mild-to-moderate disease in well-controlled ones, postponement of non urgent diagnostic work-ups and domiciliation of therapies, whenever possible. As far as therapies, allergen immunotherapy (AIT) should not be stopped and sublingual immunotherapy (SLIT) fits perfectly for this purpose, since a drug home-delivery service can be activated for the entire pandemic duration. Moreover, biologic agents for severe asthma, chronic spontaneous urticaria and atopic dermatitis should be particularly encouraged to achieve best control possible of severe disease in times of COVID-19 and, whenever possible, home-delivery and self-administration should be the preferred choice. During COVID-19 pandemic, allergists have the responsibility of balancing individual patients’ needs with public health issues, and innovative tools, such as telemedicine and digital medicine services, can be helpful to reduce the risk of viral spreading while delivering up-to-date personalized care.